Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Company Summary
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
Health Care
Biotechnology
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Announcements
Published at:
Link
No items found.